Associations between antiretroviral regimen and changes in blood pressure: results from the D2EFT study

Nyein PP 1 , Petoumenos K 1 , Borok M 2 , Eriobu N 3 , Kumarasamy N 4 , Avihingsanon A 5 Show all authors , Azwa I 6 , Dao S 7 , Cisse M 8 , Dharan NJ 1 , Hanson J 1 , Matthews GV 1

Affiliations 

  • 1 The Kirby Institute, University of New South Wales, Australia
  • 2 University of Zimbabwe Clinical Research Centre, Zimbabwe
  • 3 Institue of Human Virology Nigeria, Nigeria
  • 4 Chennai Antiviral Research and Treatment Clinical Research Site (CART CRS) Voluntary Health Services (VHS), India
  • 5 The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Thai Red Cross AIDS Research Centre, Thailand
  • 6 University of Malaya Medical Centre (UMMC), Malaysia
  • 7 University Clinical Research Centre (UCRC), Mali
  • 8 Centre de traitement ambulatoire de Donka (Hospital de jour), Guinea
Clin Infect Dis, 2024 May 09.
PMID: 38721980 DOI: 10.1093/cid/ciae256

Abstract

In this randomised, controlled study in 14 low- and middle-income countries, individuals taking dolutegravir with darunavir/ritonavir for 48 weeks had a greater increase in systolic and diastolic blood pressure than individuals taking two nucleoside reverse transcriptase with darunavir/ritonavir. The difference remained significant after controlling for confounding factors including weight gain.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications